GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Earnings per Share (Diluted)

Minerva Neurosciences (Minerva Neurosciences) Earnings per Share (Diluted) : $-4.66 (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Earnings per Share (Diluted)?

Minerva Neurosciences's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-1.20. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.66.

Minerva Neurosciences's EPS (Basic) for the three months ended in Dec. 2023 was $-1.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.66.

Minerva Neurosciences's EPS without NRI for the three months ended in Dec. 2023 was $-1.25. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.88.

During the past 3 years, the average EPS without NRIGrowth Rate was 5.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 17.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 2.50% per year.

During the past 12 years, Minerva Neurosciences's highest 3-Year average EPS without NRI Growth Rate was 42.50% per year. The lowest was -137.80% per year. And the median was 5.30% per year.


Minerva Neurosciences Earnings per Share (Diluted) Historical Data

The historical data trend for Minerva Neurosciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences Earnings per Share (Diluted) Chart

Minerva Neurosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.80 0.40 -9.35 -6.01 -4.61

Minerva Neurosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.26 -1.31 -1.12 -1.03 -1.20

Competitive Comparison of Minerva Neurosciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Minerva Neurosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's PE Ratio falls into.



Minerva Neurosciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Minerva Neurosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-30.005-0)/6.506
=-4.61

Minerva Neurosciences's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-9.022-0)/7.581
=-1.19

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Minerva Neurosciences  (NAS:NERV) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Minerva Neurosciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences (Minerva Neurosciences) Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Executives
Ag Boehringer 10 percent owner BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh 10 percent owner 200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer officer: EVP and Head of R&D C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race officer: EVP and CFO C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm officer: Chief Accounting Officer C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly officer: Chief Business Officer C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell officer: President C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle director
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd 10 percent owner 5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd 10 percent owner 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG

Minerva Neurosciences (Minerva Neurosciences) Headlines

From GuruFocus